ICML 2025 | MAIC of epcoritamab + R-miniCHOP versus R-miniCHOP in elderly patients with DLBCL

Treatment of elderly DLBCL patients remains a challenge. With R-miniCHOP that is frequently used in these settings, we are able now to cure only about half of the patients. In the Epcore NHL-2 trial, which was a Phase I and II trial, the combination of epcoritamab plus R-miniCHOP was associated with high response rates and durable progression-free survival and overall survival. To put this data into context we decided to perform a matched-adjusted comparative analysis of this data with real-world data of patients treated with R-miniCHOP from the US [inaudible] database. These data were matched using inverse probability of treatment weighting on important baseline factors including the age, gender, ECOG performance status, clinical stage and LDH, as well as cell of origin if data were known. After balancing of both groups, our analysis shows that the combination of epcoritamab plus R-miniCHOP was associated with a numerically higher overall response rate, but statistically significantly higher complete response rates of 93% versus 67% and 64% reduction of progression-free survival events and 80% reduction of risk of death. So based on our study, despite some limitations including retrospective character of the study, small numbers of patients and probably also some differences in characteristics of patients, we believe that the combination of epcoritamab plus R-mini-CHOP represents a valuable treatment option in the settings of elderly DLBCL patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.